Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Verrica Pharmaceuticals, Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) on behalf of Verrica stockholders. Our investigation concerns whether Verrica has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

Verrica is a dermatology therapeutics company that develops and commercializes treatments for people with skin diseases in the United States.

On May 24, 2022, after the market closed, Verrica announced that the U.S. Food and Drug Administration (“FDA”) had issued a Complete Response Letter regarding its New Drug Application for molluscum contagiosum treatment, VP-102. Specifically, the FDA cited “deficiencies identified at a general reinspection of Sterling Pharmaceuticals Services, LLC (Sterling), the contract manufacturing organization (CMO) that manufactures Verrica’s bulk solution drug product.”

On this news, the price of Verrica shares declined by $3.55 per share, or approximately 63.8%, from $5.56 per share to close at $2.01 per share on May 25, 2022.

If you purchased or otherwise acquired Verrica shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005063/en/